Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
23/03/2026
Moody's rating agency confirmed Rheinmetall Group's Baa1 rating and revised its outlook to positive.
Latest
3 m ago
Guangzhi Technology: Net loss of 33.1997 million yuan in 2025.
4 m ago
The Turkish bank index fell by 6.8%, reaching its lowest level since November 26 of last year.
6 m ago
The International Atomic Energy Agency reaffirms that no military action should jeopardize the safety of nuclear power plants.
6 m ago
Zhongyan Dadi: Abandoning the winning bid for the nuclear power project due to major adjustments in the implementation plan.
7 m ago
The announcement of the Group of Chinese Drug Group: The Group has developed Aprepitant Injection (4.4ml:32mg), which has obtained the drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is a new generation NK-1 receptor antagonist, a submicellar injection that can selectively bind to NK-1 receptors in the brain and antagonize substance P effectively to prevent acute and delayed vomiting. This product is suitable for preventing postoperative nausea and vomiting (PONV) in adults. Compared to traditional forms of Aprepitant, this product has a rapid onset of action, significantly improves patient compliance, and effectively reduces the occurrence of allergic reactions in clinical use. It provides a better medication choice for the prevention of postoperative nausea and vomiting in adults.
See all latest
